Article
A multicenter phase II study of sorafenib monotherapy in clinically selected patients with advanced lung adenocarcinoma after failure of EGFR-TKI therapy (Chinese Thoracic Oncology Group, CTONG 0805).
Lung cancer (Amsterdam, Netherlands) - 1 Mar 2014
Zhou Qing, Zhou Cai-cun, Chen Gong-yan, Cheng Ying, Huang Cheng, Zhang Li, Xu Chong-rui, Li Ai-wu, Yan Hong-hong, Su Jian, Zhang Xu-chao, Yang Jin-ji, Wu Yi-long
Abstract excerpt
OBJECTIVES: Aim of the study was to investigate efficacy and safety of sorafenib in patients with advanced lung adenocarcinoma after failure of epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) therapy. PATIENTS AND METHODS: Patients who were diagnosed with stage IIIB or stage IV lung adenocarcinoma, and benefited from one prior EGFR-TKI therapy and then failed, were eligible. No more than...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.